NCT05929677 Impulsivity Domains and Subjective Response
| NCT ID | NCT05929677 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Jessica Weafer |
| Condition | Alcohol Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2027-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 250 participants in total. It began in 2024-04-01 with a primary completion date of 2027-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Findings from this project will determine the relationship between two vulnerability factors for Alcohol Use Disorder (AUD) in young adults: impulsivity and subjective response to alcohol. The results will identify badly needed, novel targets for prevention and treatment efforts to simultaneously reduce impulsivity and subjective responses in at-risk young adults.
Eligibility Criteria
Inclusion Criteria: * 21-25 years old * Report drinking to an estimated BAC \> .08% at least once in the past 30 days based on responses on the Timeline Followback (TLFB) * Report drinking at least twice weekly in the past 30 days based on responses on the TLFB * Fluency in English Exclusion Criteria: * Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders) * Body weight \< 110 or \> 210 pounds * Axis I psychiatric disorders including substance use disorder other than mild or moderate alcohol or mild cannabis use disorder * Current alcohol withdrawal or history of medically-assisted detoxification * Two positive breath alcohol concentration (BrAC) readings (i.e., \> 0.00%) at an in-person screening appointment or experimental session * Positive urine screen for illegal drugs other than cannabis * Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors * Current psychotropic medication use or receipt of a prescription for these medications in the past 30 days * Psychosis or other psychiatric disability * Pregnancy, nursing or lack of reliable birth control use for women * Report smoking \> 5 cigarettes per day (to avoid acute nicotine effects or withdrawal during experimental sessions)
Contact & Investigator
Jessica Weafer, PhD
PRINCIPAL INVESTIGATOR
Ohio State University
Frequently Asked Questions
Who can join the NCT05929677 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 25 Years, studying Alcohol Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05929677 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05929677 currently recruiting?
Yes, NCT05929677 is actively recruiting participants. Contact the research team at jessica.weafer@osumc.edu for enrollment information.
Where is the NCT05929677 trial being conducted?
This trial is being conducted at Boston, United States, Columbus, United States.
Who is sponsoring the NCT05929677 clinical trial?
NCT05929677 is sponsored by Jessica Weafer. The principal investigator is Jessica Weafer, PhD at Ohio State University. The trial plans to enroll 250 participants.